当美妆以科技定价，华熙生物被低估了？

Core Viewpoint - The beauty industry is transitioning from a "traffic-driven" growth model to a "technology-driven" endurance model, necessitating a reevaluation of value assessment based on technological innovation and manufacturing capabilities [6][10]. Group 1: Policy and Industry Trends - The National Medical Products Administration released two significant documents emphasizing "raw material innovation" and the establishment of internal raw material incubators in leading companies, marking a long-term strategic direction for the beauty industry [4]. - The focus on biomanufacturing as a key future industry has been reiterated in government reports, indicating a systemic push from research to industry regulation [8]. Group 2: Company Strategy and Positioning - Companies like Huaxi Biological, which have built biotechnological and manufacturing capabilities over the past two decades, are now being reassessed for their strategic significance in the new industry landscape [5]. - Huaxi Biological's consistent investment in R&D, exceeding 2.2 billion yuan since its listing in 2019, positions it among the industry leaders in innovation [12]. Group 3: Technological Advancements - Huaxi Biological is pioneering the synthetic biology approach to PDRN production, addressing traditional issues related to safety and efficacy through innovative methods [17][18]. - The establishment of a large-scale synthetic biology pilot transformation platform, with over 3 billion yuan invested, enables the systematic conversion of research outcomes into scalable products [21]. Group 4: Market Dynamics and Valuation Logic - The market is shifting its focus from immediate sales performance to long-term capabilities, emphasizing the importance of a company's ability to anchor itself for the next five to ten years [9][10]. - Huaxi Biological's ability to maintain a stable cash flow from its raw materials and medical terminal businesses supports its ongoing R&D efforts, allowing it to navigate industry fluctuations without sacrificing long-term goals [28]. Group 5: Future Outlook - The beauty industry's core competitiveness is increasingly centered on biotechnological and biomanufacturing capabilities, as evidenced by international giants investing in similar technologies [22]. - Huaxi Biological's comprehensive biotechnological and manufacturing system is seen as a "ticket" to navigate through industry cycles, with its true value beginning to be recognized by the market [31].